{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T14:41:16Z","timestamp":1782571276296,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["322898"],"award-info":[{"award-number":["322898"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007793","name":"Stiftelsen Kristian Gerhard Jebsen","doi-asserted-by":"publisher","award":["19"],"award-info":[{"award-number":["19"]}],"id":[{"id":"10.13039\/100007793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007793","name":"Stiftelsen Kristian Gerhard Jebsen","doi-asserted-by":"publisher","award":["19"],"award-info":[{"award-number":["19"]}],"id":[{"id":"10.13039\/100007793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007793","name":"Stiftelsen Kristian Gerhard Jebsen","doi-asserted-by":"publisher","award":["19"],"award-info":[{"award-number":["19"]}],"id":[{"id":"10.13039\/100007793","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The microenvironment of chronic lymphocytic leukemia (CLL) cells in lymph nodes, spleen, and bone marrow provides survival, proliferation, and drug resistance signals. Therapies need to be effective in these compartments, and pre-clinical models of CLL that are used to test drug sensitivity must mimic the tumor microenvironment to reflect clinical responses. Ex vivo models have been developed that capture individual or multiple aspects of the CLL microenvironment, but they are not necessarily compatible with high-throughput drug screens. Here, we report on a model that has reasonable associated costs, can be handled in a regularly equipped cell lab, and is compatible with ex vivo functional assays including drug sensitivity screens. The CLL cells are cultured with fibroblasts that express the ligands APRIL, BAFF and CD40L for 24\u2009h. The transient co-culture was shown to support survival of primary CLL cells for at least 13 days, and mimic in vivo drug resistance signals. Ex vivo sensitivity and resistance to the Bcl-2 antagonist venetoclax correlated with in vivo responses. The assay was used to identify treatment vulnerabilities and guide precision medicine for a patient with relapsed CLL. Taken together, the presented CLL microenvironment model enables clinical implementation of functional precision medicine in CLL.<\/jats:p>","DOI":"10.1038\/s41420-023-01426-w","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T11:02:53Z","timestamp":1681383773000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["A tumor microenvironment model of chronic lymphocytic leukemia enables drug sensitivity testing to guide precision medicine"],"prefix":"10.1038","volume":"9","author":[{"given":"Johanne U.","family":"Hermansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Urban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla V.","family":"Myklebust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Karlsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrine","family":"Melvold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders A.","family":"Tveita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjetil","family":"Task\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0344-3654","authenticated-orcid":false,"given":"Ludvig A.","family":"Munthe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7757-4091","authenticated-orcid":false,"given":"Geir E.","family":"Tj\u00f8nnfjord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1630-356X","authenticated-orcid":false,"given":"Sigrid S.","family":"Sk\u00e5nland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,13]]},"reference":[{"key":"1426_CR1","doi-asserted-by":"publisher","first-page":"4054","DOI":"10.1182\/bloodadvances.2021005083","volume":"5","author":"TE Lew","year":"2021","unstructured":"Lew TE, Lin VS, Cliff ER, Blombery P, Thompson ER, Handunnetti SM, et al. Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition. Blood Adv. 2021;5:4054\u20138.","journal-title":"Blood Adv"},{"key":"1426_CR2","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1002\/ajh.26682","volume":"97","author":"JH Aronson","year":"2022","unstructured":"Aronson JH, Sk\u00e5nland SS, Roeker LE, Thompson MC, Mato AR. Approach to a patient with \u201cdouble refractory\u201d chronic lymphocytic leukemia: \u201cDouble, double toil and trouble\u201d (Shakespeare). Am. J. Hematol. 2022;97:S19\u201325.","journal-title":"Am. J. Hematol."},{"key":"1426_CR3","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.tips.2022.08.009","volume":"43","author":"\u00c5 Flobak","year":"2022","unstructured":"Flobak \u00c5, Sk\u00e5nland SS, Hovig E, Task\u00e9n K, Russnes HG. Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models. Trends Pharmacol. Sci. 2022;43:973\u201385.","journal-title":"Trends Pharmacol. Sci."},{"key":"1426_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ccell.2021.12.004","volume":"40","author":"A Letai","year":"2022","unstructured":"Letai A, Bhola P, Welm AL. Functional precision oncology: testing tumors with drugs to identify vulnerabilities and novel combinations. Cancer Cell. 2022;40:26\u201335.","journal-title":"Cancer Cell"},{"key":"1426_CR5","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1158\/2159-8290.CD-21-0538","volume":"12","author":"C Kornauth","year":"2022","unstructured":"Kornauth C, Pemovska T, Vladimer GI, Bayer G, Bergmann M, Eder S, et al. Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders. Cancer Discov. 2022;12:372\u201387.","journal-title":"Cancer Discov"},{"key":"1426_CR6","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-21-0410","volume":"12","author":"D Malani","year":"2022","unstructured":"Malani D, Kumar A, Br\u00fcck O, Kontro M, Yadav B, Helles\u00f8y M, et al. Implementing a functional precision medicine tumor board for acute myeloid leukemia. Cancer Discov. 2022;12:388\u2013401.","journal-title":"Cancer Discov"},{"key":"1426_CR7","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1038\/s41375-020-0846-5","volume":"34","author":"M Lukas","year":"2020","unstructured":"Lukas M, Velten B, Sellner L, Tomska K, H\u00fcellein J, Walther T, et al. Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies. Leukemia. 2020;34:2934\u201350.","journal-title":"Leukemia"},{"key":"1426_CR8","doi-asserted-by":"publisher","first-page":"E7554","DOI":"10.1073\/pnas.1703094114","volume":"114","author":"SE Kurtz","year":"2017","unstructured":"Kurtz SE, Eide CA, Kaempf A, Khanna V, Savage SL, Rofelty A, et al. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. Proc. Natl Acad. Sci. USA. 2017;114:E7554\u201363.","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1426_CR9","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1182\/bloodadvances.2020003423","volume":"5","author":"SS Sk\u00e5nland","year":"2021","unstructured":"Sk\u00e5nland SS, Mato AR. Overcoming resistance to targeted therapies in chronic lymphocytic leukemia. Blood Adv. 2021;5:334\u201343.","journal-title":"Blood Adv"},{"key":"1426_CR10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.bbamcr.2015.07.009","volume":"1863","author":"E ten Hacken","year":"2016","unstructured":"ten Hacken E, Burger JA. Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment. Biochim. Biophys. Acta. 2016;1863:401\u201313.","journal-title":"Biochim. Biophys. Acta"},{"key":"1426_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10238-013-0268-z","volume":"15","author":"AA Filip","year":"2015","unstructured":"Filip AA, Cisela B. Wasik-Szczepanek. Guilty bystanders: nurse-like cells as a model of microenvironmental support for leukemic lymphocytes. Clin. Exp. Med. 2015;15:73\u201383.","journal-title":"Clin. Exp. Med."},{"key":"1426_CR12","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1080\/10428194.2016.1204654","volume":"58","author":"K Crassini","year":"2017","unstructured":"Crassini K, Shen Y, Mulligan S, Giles BO. Modeling the chronic lymphocytic leukemia microenvironment in vitro. Leuk. Lymphoma. 2017;58:266\u201379.","journal-title":"Leuk. Lymphoma"},{"key":"1426_CR13","doi-asserted-by":"publisher","first-page":"607608","DOI":"10.3389\/fonc.2020.607608","volume":"10","author":"C Scielzo","year":"2020","unstructured":"Scielzo C, Ghia P. Modeling the leukemia microenviroment in vitro. Front. Oncol. 2020;10:607608.","journal-title":"Front. Oncol"},{"key":"1426_CR14","doi-asserted-by":"publisher","first-page":"101601","DOI":"10.1016\/j.xpro.2022.101601","volume":"3","author":"D Belloni","year":"2022","unstructured":"Belloni D, Ferrarini M, Ferrero E, Guzzeloni V, Barbaglio F, Ghia P, et al. Protocol for generation of 3D bone marrow surrogate microenvironments in a rotary cell culture system. STAR. Protoc. 2022;3:101601.","journal-title":"STAR. Protoc."},{"key":"1426_CR15","doi-asserted-by":"publisher","first-page":"639572.","DOI":"10.3389\/fimmu.2021.639572","volume":"12","author":"FV Sbrana","year":"2021","unstructured":"Sbrana FV, Pinos R, Barbaglio F, Ribezzi D, Scagnoli F, Scarf\u00f2 L. et al. 3D bioprinting allows the establishment of long-term 3D culture model for chronic lymphocytic leukemia cells. Front. Immunol. 2021;12:639572.","journal-title":"Front. Immunol"},{"key":"1426_CR16","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1182\/blood-2012-11-467670","volume":"122","author":"MF Pascutti","year":"2013","unstructured":"Pascutti MF, Jak M, Tromp JM, Derks IA, Remmerswaal EB, Thijssen R, et al. IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells. Blood. 2013;122:3010\u20139.","journal-title":"Blood"},{"key":"1426_CR17","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41598-018-36853-8","volume":"9","author":"C Schleiss","year":"2019","unstructured":"Schleiss C, Ilias W, Tahar O, G\u00fcler Y, Miguet L, Mayeur-Rousse C, et al. BCR-associated factors driving chronic lymphocytic leukemia cells proliferation ex vivo. Sci.Rep. 2019;9:701.","journal-title":"Sci.Rep."},{"key":"1426_CR18","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1182\/blood-2003-02-0540","volume":"103","author":"C Kern","year":"2004","unstructured":"Kern C, Cornuel JF, Billard C, Tang R, Rouillard D, Stenou V, et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood. 2004;103:679\u201388.","journal-title":"Blood"},{"key":"1426_CR19","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/ni792","volume":"3","author":"C Ahonen","year":"2002","unstructured":"Ahonen C, Manning E, Erickson LD, O\u2019Connor B, Lind EF, Pullen SS, et al. The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells. Nat. Immunol. 2002;3:451\u20136.","journal-title":"Nat. Immunol."},{"key":"1426_CR20","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1365-2567.2006.02377.x","volume":"118","author":"S Haiat","year":"2006","unstructured":"Haiat S, Billard C, Quiney C, Ajchenbaum-Cymbalista F, Kolb JP. Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia. Immunology. 2006;118:281\u201392.","journal-title":"Immunology"},{"key":"1426_CR21","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1046\/j.1365-2141.1999.01642.x","volume":"106","author":"S Kitada","year":"1999","unstructured":"Kitada S, Zapata JM, Andreeff M, Reed JC. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br. J. Haematol. 1999;106:995\u20131004.","journal-title":"Br. J. Haematol."},{"key":"1426_CR22","doi-asserted-by":"publisher","first-page":"17475","DOI":"10.1074\/jbc.M607313200","volume":"282","author":"ND Mineva","year":"2007","unstructured":"Mineva ND, Rothstein TL, Meyers JA, Lerner A, Sonenshein GE. CD40 ligand-mediated activation of the de novo RelB NF-kappaB synthesis pathway in transformed B cells promotes rescue from apoptosis. J. Biol. Chem. 2007;282:17475\u201385.","journal-title":"J. Biol. Chem."},{"key":"1426_CR23","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.3324\/haematol.2017.170571","volume":"102","author":"C Paiva","year":"2017","unstructured":"Paiva C, Rowland TA, Sreekantham B, Godbersen C, Best SR, Kaur P, et al. SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia. Haematologica. 2017;102:1890\u2013900.","journal-title":"Haematologica"},{"key":"1426_CR24","first-page":"e302","volume":"100","author":"R Thijssen","year":"2015","unstructured":"Thijssen R, Slinger E, Weller K, Geest CR, Beaumont T, van Oers MH, et al. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. Haematologica. 2015;100:e302\u20136.","journal-title":"Haematologica"},{"key":"1426_CR25","doi-asserted-by":"publisher","first-page":"17651","DOI":"10.1038\/s41598-018-36121-9","volume":"8","author":"JU Hermansen","year":"2018","unstructured":"Hermansen JU, Tj\u00f8nnfjord GE, Munthe LA, Task\u00e9n K, Sk\u00e5nland SS. Cryopreservation of primary B cells minimally influences their signaling responses. Sci. Rep. 2018;8:17651.","journal-title":"Sci. Rep."},{"key":"1426_CR26","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","volume":"31","author":"RH Advani","year":"2013","unstructured":"Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J. Clin. Oncol. 2013;31:88\u201394.","journal-title":"J. Clin. Oncol."},{"key":"1426_CR27","doi-asserted-by":"crossref","unstructured":"Huynh HH, Roessle C, Sauvageon H, Pl\u00c3\u00a9 A, Madelaine I, Thieblemont C, et al. Quantification of idelalisib in human plasma by ultra-performance liquid chromatography coupled to mass spectrometry in negative ionization mode. Ther. Drug Monit. 2018;40:237\u201344.","DOI":"10.1097\/FTD.0000000000000488"},{"key":"1426_CR28","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/jcph.821","volume":"57","author":"AH Salem","year":"2017","unstructured":"Salem AH, Agarwal SK, Dunbar M, Enschede SL, Humerickhouse RA, Wong SL. Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin lymphoma. J. Clin. Pharmacol. 2017;57:484\u201392.","journal-title":"J. Clin. Pharmacol."},{"key":"1426_CR29","doi-asserted-by":"publisher","first-page":"5193","DOI":"10.1038\/srep05193","volume":"4","author":"B Yadav","year":"2014","unstructured":"Yadav B, Pemovska T, Szwajda A, Kulesskiy E, Kontro M, Karjalainen R, et al. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Sci. Rep. 2014;4:5193.","journal-title":"Sci. Rep."},{"key":"1426_CR30","doi-asserted-by":"publisher","first-page":"9325","DOI":"10.1182\/blood-2022-169662","volume":"140","author":"CY Cheah","year":"2022","unstructured":"Cheah CY, Tam CS, Lasica M, et al. A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor Bgb-11417 as monotherapy or in combination with zanubrutinib (ZANU) in patients (Pts) with CLL\/SLL: preliminary data [abstract]. Blood. 2022;140:9325\u20137.","journal-title":"Blood"},{"key":"1426_CR31","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1470-2045(22)00200-5","volume":"23","author":"NC Richardson","year":"2022","unstructured":"Richardson NC, Kasamon Y, Pazdur R, Gormley N. The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint. Lancet Oncol. 2022;23:563\u20136.","journal-title":"Lancet Oncol"},{"key":"1426_CR32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3324\/haematol.2022.281266","volume":"108","author":"SS Sk\u00e5nland","year":"2023","unstructured":"Sk\u00e5nland SS, Brown JR. PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here? Haematologica. 2023;108:9\u201321.","journal-title":"Haematologica"},{"key":"1426_CR33","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/bjh.17475","volume":"194","author":"TA Eyre","year":"2021","unstructured":"Eyre TA, Preston G, Kagdi H, Islam A, Nicholson T, Smith HW, et al. A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel). Br. J. Haematol. 2021;194:69\u201377.","journal-title":"Br. J. Haematol."},{"key":"1426_CR34","doi-asserted-by":"publisher","first-page":"5124","DOI":"10.1182\/bloodadvances.2022007708","volume":"6","author":"JM Hyak","year":"2022","unstructured":"Hyak JM, Huang Y, Rogers KA, Bhat SA, Grever MR, Byrd JC, et al. Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes. Blood Adv. 2022;6:5124\u20137.","journal-title":"Blood Adv"},{"key":"1426_CR35","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1084\/jem.182.5.1265","volume":"182","author":"P Garrone","year":"1995","unstructured":"Garrone P, Neidhardt EM, Garcia E, Galibert L, van KC, Banchereau J. Fas ligation induces apoptosis of CD40-activated human B lymphocytes. J. Exp. Med. 1995;182:1265\u201373.","journal-title":"J. Exp. Med"},{"key":"1426_CR36","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/s41375-019-0569-7","volume":"34","author":"SS Sk\u00e5nland","year":"2020","unstructured":"Sk\u00e5nland SS, Cremaschi A, Bendiksen H, Hermansen JU, Thimiri Govinda Raj DB, Munthe LA, et al. An in vitro assay for biomarker discovery and dose prediction applied to ibrutinib plus venetoclax treatment of CLL. Leukemia. 2020;34:478\u201387.","journal-title":"Leukemia"},{"key":"1426_CR37","doi-asserted-by":"publisher","first-page":"4444","DOI":"10.1158\/1078-0432.CCR-22-1221","volume":"28","author":"Y Yin","year":"2022","unstructured":"Yin Y, Athanasiadis P, Karlsen L, Urban A, Xu H, Murali I, et al. Functional testing to characterize and stratify PI3K inhibitor responses in chronic lymphocytic leukemia. Clin Cancer Res. 2022;28:4444\u201355.","journal-title":"Clin Cancer Res"},{"key":"1426_CR38","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1002\/1878-0261.13153","volume":"16","author":"K Melvold","year":"2022","unstructured":"Melvold K, Giliberto M, Karlsen L, Ayuda-Dur\u00e1n P, Hanes R, Holien T, et al. Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK\/Bcl-2 inhibition in B-cell malignancies. Mol. Oncol. 2022;16:1153\u201370.","journal-title":"Mol. Oncol."},{"key":"1426_CR39","doi-asserted-by":"publisher","first-page":"9273","DOI":"10.18632\/oncotarget.23949","volume":"9","author":"IK Myhrvold","year":"2018","unstructured":"Myhrvold IK, Cremaschi A, Hermansen JU, Tj\u00f8nnfjord GE, Munthe LA, Task\u00e9n K, et al. Single cell profiling of phospho-protein levels in chronic lymphocytic leukemia. Oncotarget. 2018;9:9273\u201384.","journal-title":"Oncotarget."},{"key":"1426_CR40","first-page":"e58386","volume":"140","author":"SS Sk\u00e5nland","year":"2018","unstructured":"Sk\u00e5nland SS. Phospho flow cytometry with fluorescent cell barcoding for single cell signaling analysis and biomarker discovery. J. Vis. Exp. 2018;140:e58386.","journal-title":"J. Vis. Exp."}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-023-01426-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-023-01426-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-023-01426-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T11:05:52Z","timestamp":1681383952000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-023-01426-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,13]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1426"],"URL":"https:\/\/doi.org\/10.1038\/s41420-023-01426-w","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,13]]},"assertion":[{"value":"21 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.E.T. has received advisory board honoraria from Alexion Pharmaceuticals and Janssen-Cilag, study support from Mundipharma, and lecture honoraria from Novartis, Janssen-Cilag, Alexion Pharmaceuticals, and Mundipharma outside of this work. S.S.S. has received honoraria from AbbVie and AstraZeneca, and research support from TG Therapeutics outside of this work. BeiGene provided the compounds zanubrutinib, BGB-10188, and BGB-11417. The other authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"125"}}